Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin

NCT04166474 is registered in ClinicalTrials.gov with Helen Reynolds as lead sponsor.

NCT NCT04166474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04166474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
Lead sponsor
Helen Reynolds
Phase
Phase 4
Overall status
Completed
Start date
November 18, 2021
Completion date
February 7, 2024
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, tuberculosis